5 results match your criteria: "University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd[Affiliation]"
J Thorac Dis
February 2018
Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030, USA.
Expert Opin Orphan Drugs
May 2015
Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd, (FC10.3022), Houston, TX 77030, USA.
Introduction: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW.
View Article and Find Full Text PDFPurpose. The ability to establish consistent human tumor xenografts in experimental animals is a crucial part of preclinical investigations.The goal of this study was to develop a method of establishing a human tumor xenograft in the leg of a nude rat for evaluation of new surgical and molecular methods of treatments of human extremity sarcoma.
View Article and Find Full Text PDFNucleic Acids Res
May 2005
Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd-447, Houston, TX 77030, USA.
One of the critical problems in the short oligo microarray technology is how to deal with cross-hybridization that produces spurious data. Little is known about the details of cross-hybridization effect at molecular level. Here, we report a free energy analysis of cross-hybridization on short oligo microarrays using data from a spike-in study.
View Article and Find Full Text PDFDev Growth Differ
April 1994
Department of Biochemistry and Molecular Biology, Box 117 The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd. Houston, TX 77030.